期刊文献+

核基质蛋白22定量分析及尿液细胞学检查评估膀胱癌复发的价值研究 被引量:7

Urine Cytology and NMP22 Qualitative Assay in Diagnosis of Recurrent Bladder Transitional Cell Carcinoma
下载PDF
导出
摘要 目的评估核基质蛋白22(NMP22)定量分析与尿液细胞学检查对膀胱癌复发的诊断价值。方法选取2008—2012年在海南医学院附属医院住院的浅表性膀胱癌患者144例。在膀胱镜检查之前患者均在3 d内连续每天提供3份用于尿液细胞学检查的尿液样本以及1份用于NMP22定量分析的尿液样本。以病理组织活检作为金标准,对NMP22定量分析与尿液细胞学检查对膀胱癌复发诊断价值的灵敏度和特异度进行评估。结果 144例患者中,52例(36.1%)诊断为复发性膀胱移行细胞癌。52例膀胱癌复发患者中,41例NMP22定量分析结果为阳性,23例尿液细胞学检查为阳性。NMP22定量分析诊断膀胱癌复发的灵敏度为78.8%(41/52),特异度为69.6%(64/92),阳性预测值为59.4%(41/69),阴性预测值为85.3%(64/75);尿液细胞学检查诊断膀胱癌复发的灵敏度为44.2%(23/52),特异度为83.7%(77/92),阳性预测值为60.5%(23/38),阴性预测值为72.6%(77/106)。两种方法诊断膀胱癌复发的灵敏度和特异度比较,差异有统计学意义(χ2=6.58、5.40,P=0.01、0.02);而两种方法诊断膀胱癌复发的阳性预测值和阴性预测值比较,差异无统计学意义(χ2=3.13、0.50,P=0.08、0.48)。NMP22定量分析与尿液细胞学检查在不同分期、分级、风险分层中的灵敏度比较,差异有统计学意义(P<0.05)。NMP22定量分析联合尿液细胞学检查、NMP22定量分析联合膀胱镜检查、尿液细胞学检查联合膀胱镜检查诊断膀胱癌复发的灵敏度分别为88.5%(46/52)、98.1%(51/52)及94.2%(49/52)。结论 NMP22定量分析法可用于浅表性膀胱癌复发的检测,尤其是在低度以及中度风险的人群,但本方法也因其相对较低的特异度在使用方面受到限制。 Objective To assess the accuracy of urine cytology and urinary nuclear matrix protein 22( NMP22) qualitative assay in the diagnosis of recurrent bladder transitional cell carcinoma( TCC). Methods From 2008 to 2012,144 patients with superficial bladder TCC were included in Affiliated Hospital of Hainan Medical University. Each patient provided,every day,3 voided urine samples for cytology and 1 for NMP22 qualitative assay within 3 d prior to urethrocystoscopy. The sensitivity and specificity of urine cytology and NMP22 test were determined. Results In 144 patients,52 cases( 36. 1%) were diagnosed as recurrent bladder TCC. The sensitivity,specificity,positive predictive value,negative predictive value were 78. 8%( 41/52),69. 6%( 64/92),59.4%( 41/69),85. 3%( 64/75),respectively,in NMP22 test,and 44.2%( 23/52),83. 7%( 77 /92),60. 5%( 23 /38),72. 6%( 77 /106),respectively,in urine cytology,the difference in sensitivity and specificity was significant( χ2= 6. 58,5. 40; P = 0. 01,0. 02),that in positive or negative predictive values was not( χ2=3. 13,0. 50; P = 0. 08,0. 48). There was difference in sensitivity at different stages,grades,risk stratification between NMP22 qualitative assay and urine cytology( P 〈 0. 05). The sensitivities of NMP22 qualitative assay combined with urine cytology,NMP22 qualitative assay with cystoscopy,urine cytology with cystoscopy were 88. 5%( 46 /52),98. 1%( 51 /52),94. 2%( 49/52),respectively,in diagnosis of recurrence TCC. Conclusion NMP22 qualitative assay can be used to diagnose recurrence of TCC,especially in low- to- moderate risk groups. But this assay is restricted in use due to its low specificity.
出处 《中国全科医学》 CAS CSCD 北大核心 2014年第26期3131-3134,共4页 Chinese General Practice
关键词 移行细胞癌 膀胱肿瘤 诊断 核基质蛋白 肿瘤标志物 Transitional cell carcinoma Urinary bladder neoplasms Diagnosis Nuclear matrix protein Tumor markers
  • 相关文献

参考文献31

  • 1Akbari ME, Hosseini S J, Rezaee A, et al. Incidence of genitourinary cancers in the Islam- ic Republic of Iran: a survey in 2005 [ J ]. Asian Pac J Cancer Prey, 2008, 9 (4): 549 - 552.
  • 2Babjuk M, Oosterlinek W, Sylvester R, et al. EAU guidelines on non - muscle - inva- sive urothelial carcinoma of the bladder [ J ]. European Urology, 2008, 54 (2): 303- 314.
  • 3Jones JS, Campbell SC. Non - muscle - inva- sire bladder cancer (Ta, T1, and CIS ) [ J ]. Campbell - Walsh Urology, 2007, 9 : 2447 - 2467.
  • 4Mufti GR, Singh M. Value of random mucosal biopsies in the management of superficial blad- der cancer [J]. Eur Urol, 1992, 22 (4): 288 - 293.
  • 5Kriegmair M, Baumgartner R, Kntichel R, et al. Detection of early bladder cancer by 5 - aminolevulinic acid induced porphyrin fluores- cence [J]. JUrol, 1996, 155 (1): 109- 110.
  • 6徐晓亮,刘振湘,黄义,白志明.膀胱癌肉瘤的临床特征[J].海南医学院学报,2010,16(1):73-75. 被引量:1
  • 7Berezney R, Coffey DS. Identification of a nuclear protein matrix [ J ]. Biochemical and Biophysical Research Communications, 1974, 60 (4) : 1410 - 1417.
  • 8Cordon - Cardo G, Wartinger DD, Melamed MR, et al. Immunopathologic analysis of hu- man urinary bladder cancer. Characterization of two new antigens associated with low - grade superficial bladder tumors [J]. Am J Pathol, 1992, 140 (2): 375-385.
  • 9Soloway MS, Briggman V, Carpinito GA, et al. Use of a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the uri- nary tract following surgical treatment [ J ]. J Urol, 1996, 156 (2 Pt 1) : 363 -367.
  • 10Sarosdy MF, deVere White RW, Soloway MS, et al. Results of a multicenter trial u- sing the BTA test to monitor for and diagnose recurrent bladder cancer [ J ]. J Urol, 1995, 154 (2 Pt 1) : 383 -384.

二级参考文献29

  • 1万小平,张阳德,范春,唐冬生,周平.大肠早癌自体荧光检测系统研究 Ⅱ.大肠癌自体荧光物质——血卟啉研究[J].中国内镜杂志,1996,2(1):3-5. 被引量:7
  • 2张爱莉,倪晓辰,张伟,吴敬.卡介苗Ag85B对小鼠膀胱癌治疗作用及机制的研究[J].实用临床医药杂志,2007,11(2):36-38. 被引量:1
  • 3Droller MJ. Bladder cancer state-of-the art care [J]. CA Cancer J Clin, 1998, 48 (5) :269-284.
  • 4Saad A, Hanbury DC, McNicholas TA, et al. A study comparing various noninvasive methods of detecting bladder cancer in urine [J]. BJU Int,2002,89(4):369-73.
  • 5Raitanen MP, Marttila T, Kaasinen E, et al. The finnbladder group sensitivity of human complement factor H related protein (BTA STAT) Test and voided urine cytology in the diagnosis of bladder cancer[J]. J Urol, 2000,163 (6): 1689-1692.
  • 6Mahnert B, Tauber S, Kriegmair M, et al. Measurements of complement factor H-related protein( BTA-TRAK assay) and nuclear matrix protein( NMP-22 assay) useful diagnostic tools in the diagnosis of urinary bladder cancer ? [J] .Clin Chem Lab Med ,2003,41 ( 1 ): 104-110.
  • 7Sanchez-Carbayo M, Herrero E, Meglas J, et al. Comparative sensitivity of urinary CYFRA21-1, urinary bladder cancer antigen, tissue polypeptide antigen and NMP22 to detect bladder cancer [ J ]. J Urol, 1999, 162 ( 6 ): 1951- 1956.
  • 8Li LY, Yang M, Zhang HB, et al. Urinary fibronectin as a predictor of a residual tumour load after transurethral resection of bladder transitional cell carcinoma. [ J ]. BJU Int, 2008,102 (5) :566-571.
  • 9Schroeder GL, Lorenzo-Gomez MF, Hautmann SH, et al. A side by side comparison of cytology and biomarkers for bladder cancer detection [ J ]. J Urol,2004,172 ( 3 ): 1123.
  • 10Droller M, Effect of Intravesieal Instillations on the Human Complement Factor H Related Protein ( BTA stat) Test. [J]. J Urol, 2002,168(2):856-857.

共引文献2

同被引文献43

引证文献7

二级引证文献27

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部